Infectious disease
Pfizer hopes to step in to ensure that no trade secrets are disclosed when the regulatory agency begins to share that information.
In the last two years, the sheer volume of scientific research focused on COVID-19 has been astounding—thousands of clinical studies, dozens of vaccines and new compounds, and hundreds of approved drugs tested for efficacy against COVID-19.
Some might go as far as to consider the pharmaceutical industry as mankind’s best hope for survival. But now, as the world enters the third year of the pandemic, has that perception changed?
Much has been made about the side effects of the COVID-19 vaccines, but a new study found a startlingly high number of adverse events associated with people who received placebos in clinical trials.
The U.S. Supreme Court blocked the mandate earlier this month, stating that OSHA had overstepped its authority.
In addition to the induction of both mucosal and systemic immunity, advantages of an intranasal approach include the lack of needles, low cost and thermostability under normal refrigeration temperature.
The expert group referred to as “Supermind” shared ideas on five areas over four-weeks last year. Here are some of the highlights.
As Omicron continues to dominate globally, research is coming in every day on this highly contagious variant of SARS-CoV-2.
The FDA cited data demonstrating that both treatments are not likely to be potent against omicron and should not be authorized for use in any U.S. state, territory, and jurisdiction for the time being.
It’s a landmark no one expected or wanted — more than 70 million confirmed COVID-19 cases in the U.S. with 866,000 deaths. For that and more COVID-19 news, continue reading.
PRESS RELEASES